High riskhuman papillomavirus (HPV) testing, neural network based screening (NNS), and prediction of CIN III
| Subgroup of women | Number of women | Mean age in years (range) | Mean follow up time in years (range) |
|---|---|---|---|
| Group A analysis: women included in the analysis of high risk HPV testing and predicting incident CIN III. | |||
| Group B analysis: women included in the analysis of NNS and predicting incident CIN III. | |||
| Group C analysis: women included in the analysis of the association between high risk HPV status and NNS result. | |||
| Women with incident CIN III are younger and have a shorter follow up time when compared with women without CIN III. This is an effect of screening. The follow up time is shorter because 8/13 women with incident CIN III were diagnosed within three years of follow up. They are younger because only very few of the older women with a normal smear or borderline nuclear changes in two or more previous screening rounds will still develop CIN III. | |||
| Group A analysis | |||
| All women in this analysis | 2250 | 43.0 (34–54) | 6.4 (0.5–10.2) |
| Incident CIN III | 13 | 38.6 (34–53) | 3.9 (0.9–9.8) |
| No CIN III | 2237 | 43.0 (34–54) | 6.4 (0.5–10.2) |
| High risk HPV positive | 121 | 43.0 (34–54) | 6.1 (0.9–9.8) |
| High risk HPV negative | 2129 | 43.0 (34–54) | 6.4 (0.5–10.2) |
| Group B analysis | |||
| All women in this analysis | 653 | 42.7 (34–54) | 6.2 (0.5–10.1) |
| Incident CIN III | 13 | 38.6 (34–53) | 3.9 (0.9–9.8) |
| No CIN III | 640 | 42.8 (34–54) | 6.2 (0.5–10.1) |
| NNS abnormal (≥ Pap 2) | 30 | 43.0 (34–53) | 6.2 (0.9–9.1) |
| NNS normal (Pap 1) | 623 | 42.7 (34–54) | 6.2 (0.5–10.1) |
| Group C analysis | |||
| All women in this analysis | 731 | 42.7 (34–54) | 6.2 (0.5–10.1) |
| NNS abnormal (≥ Pap 2) | 38 | 43.2 (34–53) | 6.2 (0.9–9.1) |
| NNS normal (Pap 1) | 693 | 42.7 (34–54) | 6.2 (0.5–10.1) |
| High risk HPV positive | 121 | 43.0 (34–53) | 6.1 (0.9–9.8) |
| High risk HPV negative | 610 | 42.7 (34–54) | 6.2 (0.5–10.1) |